Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
Each year, the incidence of nonalcoholic fatty liver (NAFLD) disease increases. NAFLD is a chronic disease. One of the most common causes of NAFLD is an inadequate lifestyle, which is characterized by a lack or low physical activity and eating highly processed foods rich in saturated fat and salt an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2022/4344905 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553495966777344 |
|---|---|
| author | Sara Jarmakiewicz-Czaja Aneta Sokal Piotr Pardak Rafał Filip |
| author_facet | Sara Jarmakiewicz-Czaja Aneta Sokal Piotr Pardak Rafał Filip |
| author_sort | Sara Jarmakiewicz-Czaja |
| collection | DOAJ |
| description | Each year, the incidence of nonalcoholic fatty liver (NAFLD) disease increases. NAFLD is a chronic disease. One of the most common causes of NAFLD is an inadequate lifestyle, which is characterized by a lack or low physical activity and eating highly processed foods rich in saturated fat and salt and containing low amount of fiber. Moreover, disturbances in intestinal microbiome and the use of certain drugs may predispose to NAFLD. NAFLD is an increasingly described disease in patients with inflammatory bowel disease (IBD). Recent data also indicate a frequent coexistence of metabolic syndrome in this group of patients. Certain groups of drugs also increase the risk of developing inflammation, liver fibrosis, and cirrhosis. Particularly important in the development of NAFLD are steroids, which are used in the treatment of many diseases, for example, IBD. NAFLD is one of the most frequent parenteral manifestations of the disease in IBD patients. However, there is still insufficient information on what dose and exposure time of selected types of steroids may lead to the development of NAFLD. It is necessary to conduct further research in this direction. Therefore, patients with IBD should be constantly monitored for risk factors for the development of NAFLD. |
| format | Article |
| id | doaj-art-bf2da47c610d4d2592a1451e790b8801 |
| institution | Kabale University |
| issn | 2291-2797 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-bf2da47c610d4d2592a1451e790b88012025-02-03T05:53:50ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/4344905Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel DiseaseSara Jarmakiewicz-Czaja0Aneta Sokal1Piotr Pardak2Rafał Filip3Institute of Health SciencesInstitute of Health SciencesInstitute of MedicineInstitute of MedicineEach year, the incidence of nonalcoholic fatty liver (NAFLD) disease increases. NAFLD is a chronic disease. One of the most common causes of NAFLD is an inadequate lifestyle, which is characterized by a lack or low physical activity and eating highly processed foods rich in saturated fat and salt and containing low amount of fiber. Moreover, disturbances in intestinal microbiome and the use of certain drugs may predispose to NAFLD. NAFLD is an increasingly described disease in patients with inflammatory bowel disease (IBD). Recent data also indicate a frequent coexistence of metabolic syndrome in this group of patients. Certain groups of drugs also increase the risk of developing inflammation, liver fibrosis, and cirrhosis. Particularly important in the development of NAFLD are steroids, which are used in the treatment of many diseases, for example, IBD. NAFLD is one of the most frequent parenteral manifestations of the disease in IBD patients. However, there is still insufficient information on what dose and exposure time of selected types of steroids may lead to the development of NAFLD. It is necessary to conduct further research in this direction. Therefore, patients with IBD should be constantly monitored for risk factors for the development of NAFLD.http://dx.doi.org/10.1155/2022/4344905 |
| spellingShingle | Sara Jarmakiewicz-Czaja Aneta Sokal Piotr Pardak Rafał Filip Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease Canadian Journal of Gastroenterology and Hepatology |
| title | Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease |
| title_full | Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease |
| title_fullStr | Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease |
| title_full_unstemmed | Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease |
| title_short | Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease |
| title_sort | glucocorticosteroids and the risk of nafld in inflammatory bowel disease |
| url | http://dx.doi.org/10.1155/2022/4344905 |
| work_keys_str_mv | AT sarajarmakiewiczczaja glucocorticosteroidsandtheriskofnafldininflammatoryboweldisease AT anetasokal glucocorticosteroidsandtheriskofnafldininflammatoryboweldisease AT piotrpardak glucocorticosteroidsandtheriskofnafldininflammatoryboweldisease AT rafałfilip glucocorticosteroidsandtheriskofnafldininflammatoryboweldisease |